NCT02114775 is a Phase 1 clinical trial of Growth Hormone in Traumatic Brain Injury, sponsored by The University of Texas Medical Branch, Galveston.

Who is sponsoring NCT02114775?

NCT02114775 is sponsored by The University of Texas Medical Branch, Galveston.

What drugs are being tested in NCT02114775?

Interventions in NCT02114775: Growth Hormone, Sildenafil, Placebo.

What condition does NCT02114775 study?

NCT02114775 studies Traumatic Brain Injury.

Is NCT02114775 still recruiting?

NCT02114775 is currently completed. Last updated 5 February 2018.

Last reviewed 2018-02-05 · How we verify

NCT02114775

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)

Completed Phase 1 Last updated 5 February 2018

What this trial tests

Phase 1 trial testing Growth Hormone in Traumatic Brain Injury in 34 participants. Completed in 10 November 2017.

Timeline

12 December 2014

Primary endpoint
10 November 2017

10 November 2017

Quick facts

Lead sponsor	The University of Texas Medical Branch, Galveston
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	diagnostic
Enrollment	34
Start date	12 December 2014
Primary completion	10 November 2017
Estimated completion	10 November 2017
Sites	1 location across United States

Drugs / interventions tested

Growth Hormone — full drug profile →
Sildenafil (sildenafil) — full drug profile →
Placebo

Conditions studied

Traumatic Brain Injury — all drugs for Traumatic Brain Injury →

Sponsor

The University of Texas Medical Branch, Galveston

Who can join

Adults 18 to 60, any sex, with Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall goal is to determine whether perceptual or performance fatigue can be reduced in MTBI patients with and without growth hormone (GH) deficiency by treating them in a crossover fashion based upon GH status. A battery of functional, fatigue, cognitive, imaging and blood flow tests will be performed to assess the efficacy of the two drug interventions, Growth hormone and Sildenafil.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Growth Hormone Alters Brain Morphometry, Connectivity, and Behavior in Subjects with Fatigue after Mild Traumatic Brain Injury.
Wright T, Urban R, Durham W, Dillon EL, et al · · 2020 · cited 27× · PMID 31797721 · DOI 10.1089/neu.2019.6690
Sildenafil-Mediated Neuroprotection from Adult to Neonatal Brain Injury: Evidence, Mechanisms, and Future Translation.
Zinni M, Pansiot J, Léger PL, El Kamouh M, et al · · 2021 · cited 15× · PMID 34685745 · DOI 10.3390/cells10102766

Verify or expand the search:

Other trials of Growth Hormone

Trials testing the same drug.

NCT05447208 — Effect of GH on the Blastocyst Euploid Rate in AMA Patients · Phase 3 · recruiting
NCT05253287 — Growth Hormone in Decompensated Liver Cirrhosis · Phase 2, PHASE3 · completed
NCT05187377 — A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism · Phase 2 · completed
NCT05089344 — Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlle · NA · unknown
NCT04532554 — Growth Hormone in Obese Cases With Covid-19 · Phase 4 · withdrawn

Other recruiting trials for Traumatic Brain Injury

Currently open trials in the same condition.

NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting
NCT07455136 — A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Mon · recruiting
NCT07404761 — Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments · NA · recruiting
NCT07230002 — Effects of Moderate/Severe Traumatic Brain Injury in the Subacute or Chronic Phase on Locomotor Strategies Involved in N · NA · recruiting

Other The University of Texas Medical Branch, Galveston trials

Trials by the same sponsor.

NCT04095260 — Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes. · not yet recruiting
NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
NCT07337915 — Improving Sleep In Midlife Women · NA · recruiting
NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
NCT07087743 — Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02114775 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston
Last refreshed: 5 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02114775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing